Phase

Praxis Precision Medicines Reviews Unfavorable Outcomes from PRAX-114 Section 2/3 Monotherapy Aria Examine in Sufferers with Main Depressive Dysfunction

Medicines

Praxis Precision Medicines Reviews Unfavorable Outcomes from PRAX-114 Section 2/3 Monotherapy Aria Examine in Sufferers with Main Depressive Dysfunction

By Helena Musk / May 6, 2023

Praxis Precision Medicines, Inc. Aria Examine didn’t obtain statistical significance on the first endpoint Strategic

Faron Broadcasts US Meals and Drug Administration and Finnish Medicines Company Approval to Provoke Part I/II Bexmarilimab Mixture Research in Hematologic Malignancies

Medicines

Faron Broadcasts US Meals and Drug Administration and Finnish Medicines Company Approval to Provoke Part I/II Bexmarilimab Mixture Research in Hematologic Malignancies

By Helena Musk / August 1, 2022

Faron Prescription drugs Ltd. (“Faron” or “Firm”) Faron Broadcasts US Meals and Drug Administration and

Moleculin Receives Approval from the UK’s Medicines and Healthcare Merchandise Regulatory Company (MHRA) for Protocol Modification to Part 1a Scientific Trial of WP1122 for the Remedy of COVID-19

Medicines

Moleculin Receives Approval from the UK’s Medicines and Healthcare Merchandise Regulatory Company (MHRA) for Protocol Modification to Part 1a Scientific Trial of WP1122 for the Remedy of COVID-19

By Helena Musk / August 1, 2022

– Dosing for first-in-human Part 1a research to judge security and pharmacokinetics of WP1122 in

College of Tokyo, Astellas Enter Second Part of Strategic Partnership for Co-creation of Progressive New Medicines and Medical Options

Medicines

College of Tokyo, Astellas Enter Second Part of Strategic Partnership for Co-creation of Progressive New Medicines and Medical Options

By Helena Musk / July 30, 2022

TOKYO, April 25, 2022 /PRNewswire/ — The College of Tokyo (President: Teruo Fujii, Ph.D.) and